U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07135466) titled 'A Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor in Patients With CD22 B-cell Malignancies' on July 02.
Brief Summary: This is a phase I/II trial of T-cell expressing an anti-CD22 Chimeric-Antigen-Receptor (CAR) in patients with CD22 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed/refractory B-cell malignancies.
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
B Cell Malignancies
Intervention:
OTHER: CD22 CAR-T cells
CD22 CAR-T cells
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sheba Medical Center
Information...